We focused on two common type 2 diabetes treatments: SGLT2-inhibitors and GLP1-receptor agonists, and three outcomes: blood glucose control, heart disease, and kidney disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.